Form 4: Bio-Rad Laboratories CEO Norman Schwartz Reports Stock Transactions
SEC Form 4 Filing
Norman Schwartz, CEO of Bio-Rad Laboratories, reports the vesting of restricted stock units and subsequent disposal of shares to cover tax obligations.
Summary
- Norman Schwartz, the Chairman, President, and CEO of Bio-Rad Laboratories, reported several transactions involving Bio-Rad's Class A common stock.
- These transactions occurred between September 1, 2024, and September 3, 2024.
- The transactions involved the vesting of restricted stock units (RSUs) and the subsequent disposal of shares to satisfy tax withholding obligations.
- Specifically, the vesting of RSUs resulted in the acquisition of shares, while the disposal of shares involved selling shares at a price of $337.32 on September 1st and 2nd, and $334.31 on September 3rd.
- Following these transactions, Schwartz directly owns 438,238 shares of Bio-Rad A Common Stock and indirectly owns 13,006 shares of Bio-Rad B Common Stock by spouse and 4,060,054 shares of Bio-Rad B Common Stock by Blue Raven Partners, L.P.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation and tax obligations, with no indication of strategic shifts or concerns.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in financial analysis to gauge management's sentiment and potential future performance.
- Comparing the volume and frequency of insider transactions at Bio-Rad to those of its competitors (e.g., Danaher, Thermo Fisher Scientific) can provide insights into relative valuation and growth prospects.
- For example, if executives at a competitor are aggressively buying shares while Schwartz is selling to cover taxes, it could signal differing outlooks on their respective companies' futures.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- However, transparency in insider transactions is important for maintaining investor confidence.
Key Dates
| Date | Description |
|---|---|
| 09/03/2019 | Date of grant for 11,597 restricted stock units vesting in five equal annual installments. |
| 09/02/2020 | Date of grant for 7,220 restricted stock units vesting in four equal annual installments. |
| 09/01/2021 | Date of grant for 5,064 restricted stock units vesting in four equal annual installments. |
| 09/01/2022 | Date of grant for 8,326 restricted stock units vesting in four equal annual installments. |
| 09/01/2023 | Date of grant for 12,020 restricted stock units vesting in four equal annual installments. |
| 09/01/2024 | Vesting of restricted stock units and disposal of shares for tax obligations. |
| 09/02/2024 | Vesting of restricted stock units and disposal of shares for tax obligations. |
| 09/03/2024 | Vesting of restricted stock units and disposal of shares for tax obligations. |
| 09/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.